EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease

Rosa De Micco iD, Oriana Ciaramaglia iD, Mattia Siciliano iD, Valeria Sant'Elia iD, Claudio Cabato iD, Ferdinando Ambrosio iD, Alessandro Tessitore iD

European Journal of Neurology · 2026

DOI: 10.1111/ene.70788 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Rosa De Micco und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Napoli, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonmotor fluctuations (NMFs) in Parkinson's disease (PD) represent a heterogeneous and disabling feature often linked to pulsatile dopaminergic stimulation from oral levodopa. Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) provides 24‐h levodopa delivery, with established motor benefits but limited real‐world data on NMFs. We investigated changes in motor complications, nonmotor symptoms, and NMFs over 3 months after initiation of CSFLI.

Methods

In this prospective, single‐center, real‐world study, 66 patients with advanced PD initiated CSFLI. Longitudinal 3‐month data were available for 40 patients. Motor complications were assessed with the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV, motor severity with UPDRS Part III, and nonmotor symptoms with the Nonmotor Symptom Scale (NMSS); nonmotor fluctuations were evaluated with the Nonmotor Fluctuation Assessment questionnaire (NoMoFa). Additional validated scales assessed sleep, mood, fatigue, autonomic, and behavioral symptoms. Longitudinal changes were analyzed using paired parametric or non‐parametric tests, as appropriate, with FDR correction.

Results

After 3 months, motor complications significantly improved, with reductions in OFF time and ON time with dyskinesias. Nonmotor symptom burden also improved, with significant reductions in NoMoFa total and NMF‐OFF scores, whereas NMF‐ON remained unchanged. Improvements were also observed in sleep‐related symptoms, depressive symptoms, and quality of life, whereas apathy, autonomic symptoms, and daytime sleepiness did not significantly change.

Conclusions

CSFLI was associated with improvements in motor complications and nonmotor fluctuations, particularly OFF‐related NMFs, together with benefits in specific nonmotor symptoms. These findings provide preliminary real‐world evidence supporting a potential role of CSFLI in the management of NMFs in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaAntiparkinson AgentsHumansFemaleMaleInfusions, SubcutaneousAgedMiddle AgedCarbidopaProspective StudiesDrug Combinations

Stichwörter der Autor:innen

Parkinson's diseasefoslevodopa/foscarbidopainfusion therapiesnonmotor fluctuationsnonmotor symptoms

Substanzen

LevodopaAntiparkinson AgentsCarbidopaDrug Combinations

Autor:innen und Institutionen

  • Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Napoli, Italy.
  • Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy.

ORCID-Profile: Rosa De Micco, Oriana Ciaramaglia, Mattia Siciliano, Valeria Sant'Elia, Claudio Cabato, Ferdinando Ambrosio, Alessandro Tessitore

Zitieren

APA

De Micco, R., Ciaramaglia, O., Siciliano, M., Sant'Elia, V., Cabato, C., Ambrosio, F., & Tessitore, A. (2026). Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease. European Journal of Neurology. https://doi.org/10.1111/ene.70788

Vancouver

De Micco R, Ciaramaglia O, Siciliano M, Sant'Elia V, Cabato C, Ambrosio F, et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease. European Journal of Neurology. 2026. doi:10.1111/ene.70788

BibTeX
@article{DeMicco2026,
  author = {De Micco, Rosa and Ciaramaglia, Oriana and Siciliano, Mattia and Sant'Elia, Valeria and Cabato, Claudio and Ambrosio, Ferdinando and Tessitore, Alessandro},
  title = {Continuous Subcutaneous Foslevodopa/Foscarbidopa Improves Nonmotor Symptoms and Fluctuations in Parkinson's Disease},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70788}
}
Kostenlos starten →